简介：Primarysclerosingcholangitis（PSC）isachronicprogressiveinflammatorydiseaseaffectingthebileducts,leadingtofibrosisandeventuallycirrhosisinmostpatients.Itsetiologyisunknownandsofarnoeffectivemedicaltherapyisavailable.Livertransplantation（LTX）istheonlycurativetreatmentandatpresentPSCisthemainindicationforLTXintheScandinaviancountries.ClosetohalfofthePSCpatientsexperienceoneormoreepisodesofacutecellularrejection（ACR）followingtransplantationandapproximately1/5ofthetransplantedpatientsdeveloprecurrentdiseaseinthegraft.Inaddition,somereportsindicatethatACRearlyafterLTXforPSCcaninfluencetheriskforrecurrentdisease.Fortheseimportantpost-transplantationentitiesaffectingPSCpatients,wehavereviewedthecurrentliteratureonepidemiology,pathogenesis,treatmentandthepossibleinfluenceofrejectionontheriskofrecurrentdiseaseintheallograft.

简介：AIM:Toinvestigatewhethergenemethylationintheperitonealfluid(PF)predictsperitonealrecurrenceingastriccancerpatients.METHODS:ThegenemethylationofCHFR(checkpointwithforkheadandringfingerdomains),p16,RUNX3(runt-relatedtranscriptionfactor3),E-cadherin,hMLH1(mutLhomolog1),ABCG2(ATP-bindingcassette,sub-familyG,member2)andBNIP3(BCL2/adenovirusE1B19kDainteractingprotein3)wereanalyzedin80specimensofPFbyquantitativemethylation-specificpolymerasechainr...

简介：AIM:ToinvestigatehowweightgainafterOLTaffectsthespeedoffibrosisprogression(SFP)duringrecurrenthepatitisCvirus(HCV)infectionofthegraft.METHODS:Ninetyconsecutivepatients(63males,medianage53years;55withHCV-relatedliverdisease),transplantedatasingleinstitution,werestudied.Allwerefollowedforatleast2yearsafterOLTandhadatleastonefollow-upgraftbiopsy,performednotearlierthan1yearafterthetransplantoperation.Foreachbiopsy,asingle,experiencedpathologistgaveanestimateofboththestagingaccordingtoIshakandthedegreeofhepaticsteatosis.TheSFPwasquantifiedinfibrosisunits/month(FU/mo).Thelipidmetabolismstatusofpatientswassummarizedbytheplasmatriglycerides/cholesterol(T/C)ratio.Bodymassindex(BMI)wasmeasuredbeforeOLT,and1and2yearsafterit.RESULTS:IntheHCVpositivegroup,thehighestSFPwasobservedinthefirstpost-OLTyear.Atthattimepoint,aSFP≤0.100FU/mowasobservedmorefrequentlyamongrecipientswhohadreceivedtheirgraftfromayoungdonorandhadapre-transplantBMIvalue＞26.0kg/m2.Atcompletionofthefirstpost-transplantyear,aBMIvalue＞26.5kg/m2wasassociatedwithaT/Cratio≤1.TheproportionofpatientswithSFP＞0.100FU/modescendedinthefollowingorder:femalerecipientswithahighT/Cratio,malerecipientswithhighT/Cratio,andrecipientsofeithergenderwithlowT/Cratio.Hepaticsteatosiswasobservedmorefrequentlyinrecipientswho,inthefirstpost-transplantyear,hadincreasedtheirBMI≥1.5kg/m2incomparisontothepre-transplantvalue.Hepaticsteatosiswasinverselyassociatedwiththestagingscore.CONCLUSION:AmongHCVpositiverecipients,excessweightgainpost-OLTdoesnotrepresentafactorfavoringearlyliverfibrosisdevelopmentandmightevenbeprotectiveagainstit.